- In 2013, reduced kidney function was associated with 4% of deaths worldwide, or 2.2 million deaths.
- More than half of these deaths were cardiovascular deaths.
Maintaining kidney health may help prevent cardiovascular diseases and deaths.
Newswise — Washington, DC (April 13, 2017) — A new analysis indicates that by 2013, cardiovascular deaths attributed to reduced kidney function outnumbered kidney failure deaths throughout the world. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), provide insights on the true impact of kidney disease on societies and underscore the importance of screening for kidney disease.
Reduced kidney function can have detrimental effects on cardiovascular health, increasing individuals’ risks of congestive heart failure, heart attacks, and strokes. To understand the impact of chronic kidney disease (CKD) on cardiovascular health, Bernadette Thomas MD, MS (University of Washington), along with dozens of international collaborators as well as the International Society of Nephrology and the Chronic Kidney Disease Prognosis Consortium, estimated the prevalence of reduced kidney function categories (CKD stages 3, 4, and 5) for 188 countries at 6 time points from 1990 to 2013 as part of the Global Burden of Disease Study.
The investigators estimated that in 2013, reduced kidney function was associated with 4% of deaths worldwide, or 2.2 million deaths. More than half (1.2 million) of these attributable deaths were cardiovascular deaths, while 0.96 million were deaths from kidney failure. Compared with metabolic risk factors, reduced kidney function ranked below high systolic blood pressure, high body mass index, and high fasting blood sugar and similarly with high total cholesterol as a risk factor for disability-adjusted life years (the number of years lost due to ill-health, disability, or early death) in both developed and developing world regions.
“Understanding the true health impact of kidney disease on society necessitates considering cardiovascular as well as end-stage renal disease deaths and disability,” said Dr. Thomas. “This is especially important within the developing world, where the death rate has increased since 1990.”
Study co-authors include Kunihiro Matsushita,Kalkidan Hassen Abate, Ziyad Al-Aly, Johan Arnlov, Kei Asayama, Robert Atkins, Alaa Badawi Shoshana H. Ballew, Amitava Banerjee, Lars Barregard,Elizabeth Barrett-Connor, Sanjay Basu, Aminu Bello, Isabela Bensenor, Jaclyn Bergstrom, Boris Bikbov, Christopher Blosser, Hermann Brenner, Juan-Jesus Carrero, Steve Chadban, Massimo Cirillo, Monica Cortinovis Karen Courville de Vaccaro, Lalit Dandona,* Rakhi Dandona, Kara Estep, Joao Fernandes, Florian Fischer, Caroline Fox, Ron T. Gansevoort, Phil Gona, Orlando M. Gutierrez, Samer Hamidi, Sarah Hanson, Jonathan Himmelfarb, Simerjot K. Jassal, Sun Ha Jee, Vivekanand Jha, Aida Jimenez-Corona, Jost B. Jonas, Andre Pascal Kengne, Yousef Khader, Young-Ho Khang, Yun Jin Kim, Barbara E. K. Klein, Ronald Klein, Yoshihiro Kokubo, Dhaval Kolte, Kristine Lee, Andrew S. Levey, Yongmei Li, Paulo Lotufo, Hassan Magdy Abd El Razek,* Walter Mendoza, Hirohito Metoki, Yejin Mok, Isao Muraki, Paul M. Muntner, Hiroyuki Noda, Takayoshi Ohkubo, Alberto Ortiz, Norberto Perico, Kevan Polkinghorne, Rajaa Raddadi, Giuseppe Remuzzi, Gregory Roth, Dietrich Rothenbacher, Michihiro Satoh, Kai-Uwe Saum, Monika Sawhney, Ben Schöttker, Anoop Shankar, Michael Shlipak, Diego Augusto Santos Silva, Hideaki Toyoshima, Kingsley Ukwaja, Mitsumasa Umesawa, Stein Emil Vollset, David G. Warnock, Andrea Werdecker, Kazumasa Yamagishi, Yuichiro Yano, Naohiro Yonemoto, Maysaa El Sayed Zaki, Mohsen Naghavi, Mohammad H. Forouzanfar, Christopher J.L. Murray, Josef Coresh, and Theo Vos.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Worldwide cardiovascular and ESRD outcomes attributable to reduced GFR,” will appear online at http://jasn.asnjournals.org/ on April 13, 2017, doi: 10.1681/ASN.2016050562.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 17,000 members representing 112 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #